BMAP-27: C-terminal domain of a cathelicidin, a myeloid antimicrobial peptide precursor; BMAP-27 stands for bovine myeloid antimicrobial peptide of 27 residues; amino acid sequence in first source; GenBank X97608
Excerpt | Reference | Relevance |
---|---|---|
" However, clinical trials have been hampered by indications of toxic effects of LL-37 on mammalian cells and evidence that its antimicrobial effects are inhibited by serum." | ( Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Bodelsson, M; Ciornei, CD; Schmidtchen, A; Sigurdardóttir, T, 2005) | 0.33 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (10.00) | 18.2507 |
2000's | 6 (30.00) | 29.6817 |
2010's | 10 (50.00) | 24.3611 |
2020's | 2 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.10) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 20 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |